Checchi Capital Advisers LLC Decreases Position in Danaher Corporation $DHR

Checchi Capital Advisers LLC trimmed its position in Danaher Corporation (NYSE:DHR) by 1.5% during the 2nd quarter, Holdings Channel.com reports. The fund owned 6,004 shares of the conglomerate’s stock after selling 94 shares during the period. Checchi Capital Advisers LLC’s holdings in Danaher were worth $1,186,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Danaher by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock valued at $12,296,123,000 after acquiring an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Danaher by 3.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after acquiring an additional 612,154 shares during the period. Bank of New York Mellon Corp increased its position in shares of Danaher by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate’s stock valued at $1,800,614,000 after acquiring an additional 194,466 shares during the period. Invesco Ltd. increased its position in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after acquiring an additional 1,450,703 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Danaher by 4.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate’s stock valued at $867,168,000 after acquiring an additional 163,332 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Price Performance

NYSE:DHR opened at $215.05 on Monday. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.41. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $153.98 billion, a PE ratio of 45.75, a price-to-earnings-growth ratio of 3.06 and a beta of 0.77. The stock’s 50-day moving average price is $200.19 and its 200-day moving average price is $197.24.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm had revenue of $5.94 billion for the quarter, compared to analysts’ expectations of $5.83 billion. During the same period last year, the firm earned $1.72 EPS. The company’s quarterly revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s dividend payout ratio (DPR) is currently 27.23%.

Insider Transactions at Danaher

In related news, Director Teri List sold 2,778 shares of Danaher stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 11.20% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on DHR. Wells Fargo & Company cut their price target on Danaher from $210.00 to $205.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 23rd. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research report on Friday, June 27th. UBS Group cut their price target on Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a research report on Wednesday, July 23rd. Bank of America cut their price target on Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a research report on Monday, September 22nd. Finally, Barclays reaffirmed an “overweight” rating and set a $225.00 price target (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Seventeen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and an average price target of $245.91.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.